RESI Returns to Boston Next Week!

15 Sep

By Rory McCann, Director of Marketing & Conference Producer, LSN

RESI Boston is merely days away and the return to in-person events (not to mention RESI’s hometown) elicits a buzz that must be seen to be believed! Hosted in-person September 21-22 at the Westin Copley Place Hotel and virtually September 23, the hybrid format is designed to meet the unique needs of the global RESI community with the high-quality panels, pitching, and partnering experience expected from a decade of success. There is still time to register for a hybrid or virtual experience to book meetings with 800+ investors, strategic partners, service providers, tech hubs, and innovators across drugs, devices, diagnostics, and digital health. RESI is the premier partnering experience exclusively serving early-stage life science and healthcare. Be a part of history and join us for our first in-person event in more than two years.  Check out the RESI Boston 2022 Program Guide to learn more about next week’s lineup of events, speakers, pitching companies, and more!

RESI-Boston-2022-Banner-with-lilly-logo-1100px

Meet the Innovator’s Pitch Challenge Judges

15 Sep

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Next week’s RESI Boston will showcase 50+ Innovator’s Pitch Challenge (IPC) finalists across therapeutics, medical devices, diagnostics, digital health, and more. These companies will pitch in a live session with a panel of investor and industry expert judges and engage in Q&A. We are thankful for all the judges who will be participating and providing valuable feedback and questions to the IPC finalist companies.

Whether you are an actively fundraising early-stage company, or an active investor/strategic partner looking for targeted deal-flow, it is still not too late to register, engage in partnering meetings with attendees of interest, and join our robust program of investor panels, workshops, and pitch sessions. Below is a splash of participating judges. See you all next week!

Featured IPC Judges


Christopher Aleong
Managing Director, North America
BioEngine Capital

Paula Andrea Lengerke Diaz
Advisor
Desert Angels

Sujuan Ba
President and COO
NFCR Oncology Impact Partners

Joshua Barney
Member
Barrington Angels

Jay Batchu
Analyst
Xontogeny

Irene Blat
Sr. Dir. Search & Evaluation, Oncology
Servier

Katie Bodner Spielberg
Associate
5AM Ventures

Bruce Cohen
Venture Partner
Xeraya Capital

Ronald Dorenbos
Executive Director, Business Development, Logica
Charles River Laboratories

Aleks Engel
Partner, Novo Holdings and Director, REPAIR Impact Fund
Novo Holdings A/S

Poorya Hosseini
Partner
Camford Capital

Tomoko Ishikura
Partner
Kicker Ventures

Hanuman Jampani
Founder & President
Samrus International

Rick Jones
Partner
BioAdvance

Deb Kemper
Managing Director
Golden Seeds

Kristin King
Member
Boston Harbor Angels

James Lee
Investment Director
Photon Fund

Seo Lee
Director
SV Investment

Nancy Levy
Founder and Managing Partner
BioHealth Management, LLC

Elliot Levy
Senior Associate – Healthtech
DreamIt Health

Bo Liang
Founding Partner
Alpha Bioventure

Yuwen Liu
Founding Partner
Bohe Angel Fund

Alyssa Reisner
Director & Principal
CVS Health Ventures

Ronak Savla
Director, Strategic Ventures
Catalent Strategic Ventures

Siyu Shi
Associate
F-Prime Capital

Christopher Tan
Director, Search & Evaluation, Neuroscience and Infectious Diseases & Vaccines
Merck & Co., Inc.

Jingjing Wang
Senior Associate
Lightstone Ventures

Sally Wang
Venture Partner
Viva BioInnovator

Tad Weems
Managing Director
Agilent Technologies

Matt Weinberg
Partner
Max Ventures

Ryan Witt
Member
Tech Coast Angels

Jacqueline Young
Investor
500 Global

Z Haroon
Chairman & General Partner
Julz Co

RESI-Boston-2022-Banner-with-lilly-logo-1100px

RESI Boston Sponsors Offer Insight & Highlight Innovation

15 Sep

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

The RESI community is built up of powerful players and innovators in the early-stage life science and healthcare arena, and Life Science Nation (LSN) welcomes them back to an in-person RESI next week at the Westin Copley Place Hotel in Boston, MA. We are pleased to highlight our sponsors, not only for their impact on the quality of meetings and partnering but also for their insights and opportunities presented through their panels and workshops. Check out who will be presenting at RESI Boston next week and learn how you can get involved.

Wednesday, September 21, 11 AM EDT

Negotiating Term Sheets Workshop: What’s Best for the Company and What’s Best for You?

Matthias Breugelmans, CEO, Elastrin Therapeutics Inc.
Nancy Briefs, President & CEO, AltrixBio, Inc.
David Hendren, Managing Director, Augmentum Ventures
Mark Mihanovic, Partner, McDermott Will & Emery
Richard Smith, Counsel, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

Wednesday, September 21, 1 PM EDT

Shinhan Square (S2) Bridge: Showcasing Innovative Technologies from South Korea
With the motto of “One Place, One Platform”, Shinhan Square Bridge (S2 Bridge) Incheon is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub. S2 Bridge Incheon is a proud Gold Sponsor of RESI Boston 2022, and we are excited to showcase 7 promising early-stage companies representing a wide variety of life science & healthcare technologies.

Wednesday, September 21, 3 PM EDT

Leveraging IP for Growing an Investable MedTech Company
Bryan Stewart Partner, Husch Blackwell (Moderator)
Cambre Kelly, PhD, Co-Founder & CEO, Reselute; Co-Founder & Vice President, Research & Technology restor3d
Adam T.C. Steege, Founder & President, Trio Labs
Timothy J. Skapek, CTO & Co-Founder, Protect3d
This panel for industry leaders, entrepreneurs, general counsel, and investors explores how investable healthcare entities leverage intellectual property (IP) to drive growth. Hear from medtech entrepreneurs about their experiences with IP strategy, protection, licensing, and marketing, and how these and other factors have impacted success.

In addition to these events, LSN is also pleased to offer a series of entrepreneurial workshops to tackle the nuts and bolts of building a brand and message, learning to tell your company story through these modalities, and sourcing a global target list.

Thursday, September 22, 11 AM EDT

Branding & Messaging
Claire (Chae-Kyeong) Jeong, Vice President, Investor Research & Asia Business Development, Life Science Nation
Candice He, Vice President, Business Development & Global Investment Strategist, Life Science Nation

The Branding & Messaging workshop discusses how to brand you and your firm and how to provide potential investors with high-quality, professional collateral—materials that engage them, communicate your message clearly and concisely, and present the information they want to see in a way that helps them to decide quickly and easily if you are a potential fit for their needs.

Thursday, September 22, 1 PM EDT

It All Starts with Your Story
Dennis Ford, Founder & CEO, Life Science Nation
Alex Vassallo, Business Development Manager West Coast, Entrepreneurial Education Lead, Life Science Nation

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

Thursday, September 22, 13 PM EDT

Identifying Your Global Target List
Gregory Mannix, Vice President, International Business Development, Life Science Nation
Karen Deyo, Director of Research, Israel Business Development, Life Science Nation

The Fundraising Boot Camp provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the changing investor landscape, new categories of life science investors, and how to organize and execute a successful roadshow. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors

RESI-Boston-2022-Banner-with-lilly-logo-1100px

Hot Investor Mandate: Corporate Venture Arm of Large Materials Engineering Company Seeks to Invest in Early & Growth-Stage Companies With Strategic Alignment

15 Sep

Corporate venture arm of a large company has set up their fund with $100M to invest each year, with a portion of that going to investments in the life sciences. Within the life sciences, the firm is looking for investments that are both financial and strategic, and will only consider companies that can make use of the parent company’s expertise, or those that align with new strategic areas of interest. The firm is interested in companies with technologies in diagnostic, imaging, omics tools and pharmaceutical manufacturing processes. The firm invests globally, and will consider companies from prototype stage and on. The firm mostly invests in companies at Series B and later, but will consider Series A opportunities as well, and will invest between $0.5-7M per round.

The firm is interested in technologies that can make use of the parent company’s expertise in semiconductors, display, and material engineering. Examples of potential areas of interest include imaging technologies that adapt the company’s inspection ability to detect defects on a nano scale, diagnostics platforms making use of semiconductors or other novel materials as part of their instrumentation and devices, or companies that can adapt the parent company’s advanced manufacturing to control chemical deposition and use different time release formulations to advance drug delivery techniques.

The firm can lead or co-invest, but will take a board observer seat when co-investing, and a board seat when acting as a lead. The firm looks to invest in companies where the expertise of the parent company is applicable to moving the technology forward.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Capital Firm Under China-Headquartered Company Actively Seeks North America-Based Investment Opportunities in Therapeutics, Devices, and Diagnostics

15 Sep

A specialized US venture capital firm under a large China-headquartered company conducts business with a sister company as one group.  The firm has an additional virtual office in USA. The firm is actively seeking investment opportunities from early stage to pre-IPO rounds.  The average size of investment is ~ $5M.  The firm has invested in 17 US & Canada companies since 2016.  The firm can act as the lead investor or co-investor depends on different cases, and the firm prefers to have a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm will also consider orphan drugs and digital health companies.  The firm is open to all kinds of sectors. The firm is open to medical devices with all FDA regulatory pathways, including 510k and PMA.  The firm is open to any phases in medical devices and therapeutics. However, the firm will invest in private companies only.

The firm has no specific requests on the management team.  The firm generally takes a board seat.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm in US With Billions AUM Invests Across All Life Science Modalities Across the Globe, With Strong Focus on Early-Stage Technologies

15 Sep

A VC firm headquartered in US has over USD 2.8 billion in assets under management, the firm will consider participating in financing companies throughout all stages but tends to prefer those that are early stage. The firm currently manages a variety of funds and invests in early-stage startups out of a dedicated fund with typical allocations between $150-500k. The firm utilizes various capital structures as determined on a case- by-case basis and has experience with equity investments, debt, convertible loans, and SAFEs. The firm focuses on investment quality over quantity and likes to emphasize being a globally connected firm that will invest regardless of geography.

The firm focuses on markets and founders that are developing technologies with long-term value and growth potential. In the life sciences, the firm is completely sector agnostics and will invest across all modalities within biotechnology, medical technology, digital health, and diagnostics. The firm tends to have a higher bar for biotech and pharma investments compared to the other life science modalities. The firm is phase agnostic and will invest in pre-clinical to on the market therapeutics as well as in development to on the market devices. The firm will invest in all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will consider companies across all indications.

The firm will work with both experienced and inexperienced management teams that are made up of smart and driven people that are passionate and knowledgeable about their company and technology. The firm will take a board seat as determined on a case-by-case basis and will participate as both a lead and co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm Seeking Breakthrough Healthcare Technologies in US, Europe, and Asia, With Interests in Synthetic Biology, Genomics, AI/ML Applications, and More

15 Sep

A venture capital firm invests in breakthrough technologies changing healthcare. The firm invests from pre-see/seed/pre-A. The fund’s LP’s include groups in the healthcare sector. The firm invests in USA, Europe, and Asia.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: